Vadodara: The National Dairy Development Board ( NDDB ) on Wednesday announced that the Indian Immunologicals Limited ( IIL ), its wholly-owned subsidiary, has developed a live-attenuated needle-free intranasal booster vaccine against SARS-CoV-2 using codon deoptimisation technology in collaboration with Griffith University, Australia. The research work on the Covid-19 vaccine has been published in the world’s leading science journal, Nature Communications. “IIL’s needle-free intranasal booster vaccine for SARS-CoV-2 has demonstrated impressive stability and safety in extensive animal studies,” a release issued by NDDB said, adding that Covid-19 continues to claim the lives of around 1,700 people worldwide each week.
“The World Health Organization (WHO) is urging those at risk to stay up to date with their vaccinations with boosters. Among the various types of vaccines available, it is widely recognised that live attenuated vaccines generate a robust and broad-spectrum neutralising antibody response,” the release mentioned. “The pioneering work done by IIL in collaboration with Griffith University, Australia, introduced a new approach to combat infectious diseases using codon deoptimised live attenuated vaccines,” said NDDB and IIL chairman Dr Meenesh Shah.
“Our R&D team has put immense effort into creating this innovative vaccine and are proud of its proven safety and efficacy in generating a protective immune response with just a single dose,” he said. “The development of this vaccine not only highlights our dedication to innovation in public health but also demonstrates IIL’s capability in adopting novel technology. We are enthusiastic about the codon deoptimisation technology and its use in the targeted attenuation of microorganisms to be used as vaccine candidates,” said Dr K Anand Kumar, managing director of IIL.
We also published the following articles recently Hyderabad's IIL develops live-attenuated vax for Covid-19 Indian Immunologicals, in partnership with Griffith University, has produced a new live-attenuated intra-nasal booster vaccine for Covid-19. The vaccine, published in 'Nature Communications', exhibits robust immunity and stability in animal tests, utilizing codon deoptimization technology. The WHO stresses the importance of booster vaccinations given the continued global threat of Covid-19.
New Covid vaccines targeting KP.2 variant approved; 5 things to know The FDA has approved updated Pfizer and Moderna Covid-19 vaccines aimed at the KP.2 variant.
Available for those aged six months and older, these shots address the current rise in cases and hospitalizations. They focus on protecting high-risk groups like the elderly and immunocompromised, providing enhanced defense against severe disease. Mpox: Germany to give Africa 100,000 doses of vaccine Germany will donate 100,000 doses of mpox vaccine to the Democratic Republic of Congo and other African nations, reducing its military reserve.
Berlin will also provide financial aid to the WHO and Gavi Vaccine Alliance. This follows a new, deadly strain of mpox that has rapidly spread across several countries in Africa..
